Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation
Top Cited Papers
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 57 (2), 173-180
- https://doi.org/10.1016/j.jacc.2010.09.024
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- AstraZeneca
- Boehringer
- Nayer
- Pfizer/BMS
- Biotronic
- Astellas
- Sanofi
- Cardiome
- Merck
- Bayer HealthCare
This publication has 24 references indexed in Scilit:
- Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled ‘research perspectives in atrial fibrillation’EP Europace, 2009
- Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patientsThrombosis and Haemostasis, 2009
- Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial FibrillationStroke, 2008
- Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic reviewQJM: An International Journal of Medicine, 2007
- Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial FibrillationCell Metabolism, 2007
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Avoiding Central Nervous System Bleeding During Antithrombotic TherapyStroke, 2005
- Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation PatientsStroke, 2004
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Physician variation in the management of patients with atrial fibrillation.Heart, 1996